Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two(Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccines in Non-Elderly Adult and Elderly Subjects

PHASE2CompletedINTERVENTIONAL

Enrollment

520

Participants

Timeline

Start Date

March 31, 2006

Conditions

Pandemic Influenza Disease

Interventions

BIOLOGICAL

Influenza vaccine surface antigen adjuvanted with MF59

Trial Locations (4)

Department of Health Sciences, Genoa

University Hospital of Siena, Siena

ASL Lanciano-Vasto, Lanciano

G. D'Annunzio University, Chieti